Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Opinion

Thapsigargin: key to new host-directed coronavirus antivirals?

Mohammed Samer Shaban,1 Christin Mayr-Buro,1 Johanna Meier-Soelch,1 Benadict Vincent Albert,1 M. Lienhard Schmitz,2,3 John Ziebuhr,4,5 and Michael Kracht1,3,*

Despite the great success of vaccines that protect against RNA virus infections, and the development and clinical use of a limited number of RNA virus-specific drugs, there is still an urgent need for new classes of antiviral drugs against circulating or emerging RNA viruses. To date, it has proved difficult to efficiently suppress RNA virus replication by targeting host cell functions, and there are no approved drugs of this type. This opinion article discusses the recent discovery of a pronounced and sustained antiviral activity of the plant-derived natural compound thapsigargin against enveloped RNA viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza A virus. Based on its mechanisms of action, thapsigargin represents a new prototype of compounds with multimodal host-directed antiviral activity.

Activation of endoplasmic reticulum stress by the natural compound thapsigargin, an emerging new principle to combat coronavirus infections

The endoplasmic reticulum (ER) (see Glossary) is a large, perinuclear organelle that, in a dynamic manner, surveys the folding, assembly, transport, and degradation of membrane and secreted proteins [1]. The accumulation of unfolded or misfolded proteins in the ER lumen leads to the ER stress response and the unfolded protein response (UPR), a broad adaptive program that serves to increase the folding capacity of the ER and to restore protein homeostasis [2]. In general, ER stress and UPR act in concert and enable cells to detect and cope with misfolded proteins [3]. There is now strong evidence that this adaptive program is also activated in a broad range of cell types infected with intracellular pathogens [4]. In many cases, however, it remains unclear to what extent this cellular response is beneficial or detrimental to the pathogen (and/or host), and whether the interconnections of these processes can be pharmacologically tackled to help control the invading pathogen and thus ensure cell survival.

Both ER stress and the UPR can also be activated by chemicals, including thapsigargin, a natural compound that was isolated from the plant Thapsia garganica L. nearly 40 years ago [5]. Since then, thapsigargin has been used extensively to study its roles in (i) blocking calcium regulation, (ii) activating ER stress/UPR responses (by calcium depletion of the ER, see later), and (iii) mediating cytotoxicity [6].

In this opinion article, we highlight a newly discovered link between thapsigargin-mediated ER stress activation, UPR, and coronavirus (CoV) replication. As discussed later, there is now strong evidence that thapsigargin has antiviral effects and, based on a number of recent publications, it seems reasonable to suggest that this compound might pave the way for a new class of broad-spectrum antivirals against CoVs and, most likely, several other classes of enveloped RNA viruses.
CoV-associated changes in the ER structure and function as potential drug targets

Coronaviruses (CoVs) are enveloped and contain four major structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. The N protein encapsidates the large single-stranded, positive-sense RNA genome (+ssRNA) [7]. Cell entry is initiated by the interaction between the S protein and a cellular receptor. The subsequent fusion between viral and cellular membranes requires proteolytic cleavage by specific cellular proteases located at the plasma membrane or in endosomes, and leads to the release of the viral genome RNA, which is then translated into two large polyproteins (pp1a and pp1ab) which are proteolytically processed into individual nonstructural proteins (nsps) that together form the viral replication and transcription complex (vRTC). Specific components of the vRTC trigger a major reorganization of intracellular membrane structures, resulting, for example, in double-membrane vesicles (DMVs), zipped ER or convoluted membranes (CMs), and double-membrane spherules (DMSs). New 3D ultrastructural studies of SARS-CoV-2-infected cells provide strong evidence that viral RNA synthesis occurs inside ER-derived DMVs, which are considered as the major replicative organelles (ROs) [8–11]. In the course of infection, newly translated structural proteins translocate from ER membranes to the ER-to-Golgi intermediate compartment (ERGIC). Guided by interactions of newly formed nucleocapsids with other structural proteins, virus particles are formed by budding into the lumen of secretory vesicular compartments, and are released from the cell through the secretory exocytic pathway [7]. This brief summary shows that key steps of the CoV replication cycle involve interactions with a large variety of cytoplasmic membranes, most prominently ER membranes [12–14]. Although the molecular details of how viral and cellular factors interact to trigger the profound membrane rearrangements in CoV-infected cells are not completely understood, the available information provides a solid basis to suggest that these processes may be attractive targets for antiviral therapies.

The discovery of the inhibitory effects of thapsigargin on CoV replication

In a recent study aimed at identifying commonalities and differences between mechanisms involved in canonical ER stress and CoV-mediated ER stress response, respectively, Shaban et al. used thapsigargin as a reference compound, as done before by many other groups working in this field; their study revealed that thapsigargin strongly inhibits the replication of human CoV 229E (HCoV-229E), MERS-CoV, SARS-CoV-2, and influenza A virus (IAV, strain KAN-1) in cell culture [15]. Altogether, thapsigargin was found to interfere with coronavirus replication at multiple levels, including viral RNA synthesis and genome replication, protein translation, and production of infectious virus progeny in different cell types [15].

The antiviral effect was observed with a half-maximal effective concentration (EC50) in the lower nM range, well below the (known) half-maximal cytotoxic concentrations (CC50) of thapsigargin [15]. The inhibitory effect was readily detectable, even when the compound was added as late as 8 h postinfection (p.i.). Moreover, the effect appeared to be remarkably long-lasting, with a single drug application being sufficient to suppress viral replication for up to 3 days [15]. Shortly after the paper by Shaban et al. was published as a preprint [16], Al-Beltagi et al. reported that thapsigargin has similar inhibitory effects on HCoV-OC43, respiratory syncytial virus (RSV), SARS-CoV-2, and various IAV H1N1 strains [17]. Both groups independently confirmed the suppression of SARS-CoV-2 replication in normal human differentiated bronchial epithelial (NHBE) cells grown at an air–liquid interface [15] or in undifferentiated NHBE cells [17,18], which were used as ex vivo models mimicking the natural site of infection in humans. In a follow-up study, Al-Beltagi et al. showed that thapsigargin also suppresses the SARS-CoV-2 Alpha, Beta, and Delta variants of concern [19]. The selectivity indices (CC50/EC50) reported in these studies ranged from >70 (for SARS-CoV-2) to >900 (for IAV, RSV, MERS-CoV, HCoV-229E, and HCoV-OC43) [15,17,18]. Taken together, these studies strongly support the idea that
Thapsigargin may be developed into a broad-spectrum anti-CoV drug for application in the upper respiratory tract, and warrants further preclinical and clinical studies.

**How does thapsigargin work at the molecular level?**

In the following sections we discuss recent observations that, mechanistically, the profound antiviral activity of thapsigargin is linked to the simultaneous interference with several interconnected cellular processes and pathways.

The differential effects of PERK inhibitors and thapsigargin on CoV replication

Shaban *et al.* went on to perform a detailed molecular study to obtain more insight into how thapsigargin inhibits viral replication. Both thapsigargin and CoV infection activate the PERK protein kinase, a major ER stress sensor that phosphorylates eukaryotic translation initiation factor (eIF) 2α to block protein translation [20]. A highly selective PERK inhibitor, GSK2656157, was shown to suppress viral replication of MERS-CoV and HCoV-229E by approximately one order of magnitude, but failed to abrogate the more than 100-fold suppression of replication resulting from treatment with thapsigargin [15]. These data show that PERK has a role in the replication of (at least some) CoVs. In contrast, thapsigargin appears to act downstream of PERK, and was shown to block the replication of all human CoVs investigated so far, as discussed earlier. It thus appears possible that PERK inhibitors might be further developed into strain-specific CoV antivirals, while thapsigargin appears to have a much more potent and broad-spectrum antiviral activity.

Thapsigargin relieves translational arrest and induces proteome-wide changes in metabolic pathways in CoV-infected cells

In previous transcriptome studies unrelated to viral infections, thapsigargin was reported to cause multiple changes in cellular mRNA expression, thereby significantly extending the list of changes that are typically involved in physiological adaptive UPR responses induced by an excess of folding-competent or folding-defective model protein substrates targeted to the ER [21,22]. These data suggested that additional mechanisms contribute to the phenotypes observed for thapsigargin-treated cells.

It was also unknown to what extent thapsigargin-induced mRNA changes correlate with changes in the proteome, in particular under conditions of the profound global translational shutdown that is typically observed in RNA virus-infected cells. Along with a strong activation of PERK, CoV infection was found to reduce cellular protein biosynthesis by about 90%. Thapsigargin treatment of infected cells was observed to improve translation rates significantly. Together with data from cell viability assays, these results suggest that the compound improves, but does not completely restore, the overall metabolic status of infected cells [15].

To address these points, Shaban *et al.* performed comparative proteomic and bioinformatics studies of cells infected with MERS-CoV and SARS-CoV-2, respectively. **(Pathway) enrichment analysis** revealed a thapsigargin-mediated activation of a broad spectrum of metabolic pathways which, probably, contribute to the protective response mounted in infected cells that were treated with this compound [15].

To further corroborate the significance of these observations, it will be important to define the enzymes and their metabolites that contribute to the thapsigargin-mediated metabolic changes in infected host cells, and to answer the question of whether metabolic reprogramming can be exploited as a general (cell-intrinsic) strategy to suppress RNA virus replication.
Thapsigargin changes expression levels of proteins that regulate membrane compartments
At the level of individual components, Shaban et al. identified a set of proteins that are specifically induced (120 proteins) or downregulated (63 proteins) in thapsigargin-treated and simultaneously infected cells, as shown in Figure 7 of their publication [15]. Many of the upregulated factors are annotated as being involved in the regulation of intracellular membrane compartments (ER, Golgi apparatus-associated vesicle biogenesis and transport, endocytosis) and membrane-associated processes such as ER stress and ER-associated protein degradation (ERAD, Box 1) [15]. As discussed above, membrane rearrangement and fusion events are major hallmarks of the coronavirus replication cycle and are critically involved in virus entry, replication, and budding [8–10]. Based on the proteomic data, it is tempting to suggest that thapsigargin prevents, or activates, unknown membrane-associated processes that counteract efficient viral replication. To elucidate the underlying mechanisms, it will be important to study individually the (enzymatic) activities, interactomes (i.e., protein–protein interactions and networks), localizations, and functions of each of the specific factors identified by proteomics. Ideally, this approach should also include information from the plethora of proteomic, interactomic, and CRISPR/Cas9-based single-guide (sg) RNA genome-wide screens that have been performed recently for SARS-CoV-2 and other coronaviruses [23–29]. We firmly believe that such studies could provide new avenues for antiviral approaches that target very specifically the profound structural and functional changes in intracellular membrane compartments in +RNA virus-infected cells.

Thapsigargin induces multiple ER quality control (ERQC) and ERAD factors
There are multiple connections between ERQC, ERAD, the ubiquitin proteasome system (UPS) and autophagy pathways as outlined in Box 1. ERAD is a UPR-activated degradative mechanism that serves to retrotranslocate misfolded proteins from the lumen or membrane of the ER into the cytosol, whereupon they get ubiquitinylated and proteasomally hydrolyzed [30]. The regulation of ERAD and the related process called ER-phagy by viruses is incompletely understood [31,32]. The proteomic analyses mentioned earlier revealed that thapsigargin induces a strong upregulation of several ERAD factors, including homocysteine-responsive endoplasmic

Box 1. ERQC, ERAD, ER-phagy/autophagy and protein degradation
One third of mammalian proteins are synthesized in the ER whose maturation is overseen by the ERQC system. ERQC employs lectin chaperones or the chaperone BiP (in concert with ER-localized cofactors) that, together with protein disulfide- or peptidylprolyl isomerases, catalyze protein-folding reactions. Accurately folded and assembled proteins are released from chaperones, exit the ER, and are transported to the Golgi via coat complex II (COPII) vesicles to their final destinations. If ERQC fails, proteins will be disposed of by two degradative systems: ERAD or ER-phagy. ERAD encompasses the identification of misfolded proteins, their retrotranslocation to the cytosol, and degradation by the UPS. ERAD clients first bind to SelIL which interacts directly with the E3 ligase HRD1. By oligomerization of its transmembrane domains, HRD1 forms the central, funnel-like structure of the retrotranslocon. Upon insertion into the HRD1 channel, the client starts to cross the ER membrane, reaches the cytosol, and becomes (poly)-ubiquitinylated by HRD1. At this point, the AAA-ATPase, p97, is recruited to the ER membrane via its association with valosin-containing protein-interacting membrane protein (VIMP), recognizes the polyubiquitin chains on the ERAD client, and provides the final energy to extract it fully from the ER membrane. The ERAD client is then delivered to the 26S proteasome and degraded. ERAD involves many additional (UPR-regulated) proteins as assessed by large-scale screens [73]. ER-phagy, a (macro)autophagy-related process, is used to remove larger proteins, protein aggregates, and damaged ER, and to reduce ER size after stress-induced expansion. During autophagy, multiple autophagy-related (ATG) proteins cooperate to elongate and bend pieces of membrane to engulf cytoplasmic components or organelles. The resulting structure, the autophagosome, is decorated with phosphatidylethanolamine (PE)-conjugated, lipidated LC3 (LC3-I) at the inner side of the lipid bilayer membrane. In case of selective autophagy, substrates often carry ubiquitin chains to tether them to specific autophagy receptors (e.g., p62/SQSTM1). Mammalian ER-phagy is promoted by six ER-resident receptors (FAM134B, RTN3L, COPS1, SEC62, TEX264, and ATL3) that possess LC3-interacting regions (LIR). LIR domains help to recruit autophagy substrates to the interior of the autophagosome precursor, called isolation membrane or phagophore. To complete autophagy, the pore in the phagophore closes, and the outer autophagosomal membrane fuses with the lysosome, resulting in disintegration of the inner autophagosomal membrane and degradation of the sequestered materials (for excellent reviews on these topics see [30,74–76]).
Key figure
Hypothetical antiviral mechanism of thapsigargin involving endoplasmic reticulum (ER)-associated protein degradation (ERAD)

Figure 1. The scheme shows the organization of the ER membrane-associated ERAD complex as recently reviewed [30]. ERAD is intimately linked to the major proteasomal and autophagy-related protein degradation pathways [70–72] (Box 1). Red colors highlight the proteins endoplasmic reticulum chaperone binding immunoglobulin protein (BiP; GRP-78, HSPA5), homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 (HERPUD1), ubiquitin-like modifier-activating enzyme 6 (UBA6), autophagy-related protein LC3 (microtubule-associated proteins 1A/1B light chain 3A/B), and ubiquitin-binding protein p62/sequestosome-1 (p62/SQSTM1) that, by mass spectrometry and immunoblotting, have consistently been found to be induced by thapsigargin in coronavirus (CoV)-infected cells. Question marks indicate potential functional links between these factors. Because thapsigargin-treated infected cells show a strong

(Figure legend continued at the bottom of the next page.)
reticulum-resident ubiquitin-like domain member 1 (HERPUD1), a central scaffold for ERAD complexes assembling in the ER membrane [33] (Figure 1, Key figure). Thapsigargin also induced proteins involved in ubiquitylation and ubiquitin-like post-translational modifications. Ubiquitylation of target proteins proceeds in three steps through ubiquitin-activating (E1), -conjugating (E2) and -ligating (E3) enzymes [34]. Shaban et al. observed an upregulation of ubiquilins (UBQLN 1 and 4), the E2 enzyme ubiquitin-conjugating enzyme E2 G1 (UBE2G1), and the E1 enzyme ubiquitin-like modifier-activating enzyme 6 (UBA6) in cells infected with HCoV-229E, MERS-CoV, and SARS-CoV-2, respectively [15]. UBA6 and ubiquitin-activating enzyme E1 (UBE1, also called ubiquitin-like modifier-activating enzyme 1, UBA1) are the two main E1 enzymes that redirect proteins to the proteasome [35]. UBA6 can also activate the ubiquitin-like protein (UBL) FAT10 (also called ubiquitin D, UBD) and transfer FAT10 to its substrate proteins for rapid proteasomal destruction [35,36]. FAT10 is upregulated by the proinflammatory mediators interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), or lipopolysaccharide (LPS), and has been found to modify ubiquitin-binding protein p62/sequestosome-1 (p62/SQSTM1), connecting this pathway to autophagy and suggesting a broader role for FAT10 in immune functions [37]. These results suggest a role for specific components of the UPS in viral protein turnover downstream of ERAD/autophagy. Therefore, it is an intriguing hypothesis that the thapsigargin-mediated autophagic block described below redirects CoV proteins to an increased ERAD, thereby contributing to their rapid clearance and, as a result, suppression of viral replication (Figure 1).

Thapsigargin blocks (selective) autophagy flux
Another factor that is consistently found to be regulated by thapsigargin is p62/SQSTM1 (Box 1, Figure 1), a multifunctional signaling protein and cargo receptor for selective autophagy clients [38]. The potential role of (macro)autophagy in CoV replication is under active debate, with evidence for both proviral and antiviral functions, depending on the virus strains or model systems used (reviewed in [39,40]). As shown in the study by Shaban et al., HCoV-229E, MERS-CoV, or SARS-CoV-2 infections downregulate the level of p62/SQSTM1, albeit to a different extent. All three viruses have comparably limited effects on LC3B-II, which is the lipidated (i.e., phosphatidylethanolamine-conjugated) form of autophagy-related protein LC3B/microtubule-associated proteins 1A/1B light chain 3B (Atg8/LC3B), a ubiquitin-like molecule or modifier (ULM) that is essential for autophagosome formation early in the autophagy pathway [41]. Autophagy is a highly dynamic process that proceeds through several steps until the respective membrane-engulfed cargo is degraded by fusion of autophagosomes with lysosomes [42]. The activity of this pathway is commonly assessed by determining the turnover of autophagy proteins, which is generally referred to as the autophagic flux [43]. Application of bafilomycin A1, an inhibitor of the lysosomal enzyme V-ATPase, to CoV-infected cells resulted in (i) a strong increase in the p62 (and, to lesser extent, LC3B-II) protein levels, and (ii) a tenfold reduction in viral titers for some of the CoVs included in this study [15]. These results are in line with (more variable) antiviral effects observed for several other lysosomal inhibitors, including (hydroxy)chloroquine [44]. Taken together, the available data indicate that human CoVs stimulate selective autophagy at some point during viral replication, but clearly more evidence is needed to corroborate this hypothesis. In the presence of thapsigargin, strongly increased levels of p62/SQSTM1 and LC3B were observed in virus-infected cells by a bafilomycin A1-independent mechanism. Also, thapsigargin strongly inhibited the autophagic flux in these cells [15]. These results are best reconciled with the work by Ganley et al. who
showed that, independently of ER stress signaling and the endosomal pathway, thapsigargin blocks the fusion of autophagosomes with lysosomes late in the autophagy pathway by an unknown mechanism \[45,46\]. It is therefore possible that such a mechanism (irreversibly) prevents the correct fusion of lysosomes with intracellular vesicles throughout the CoV replication cycle and, possibly, also interferes with membrane fusion events required for the formation of replicative organelles early in the infection cycle \[7\].

**Calcium-related effects of thapsigargin**

The best understood mechanism of the action of thapsigargin is related to intracellular calcium homeostasis \[47\]. Thapsigargin was first described as a modulator of the Ca\(^{2+}\)-dependent histamine release from mast cells \[48–50\]. Functional and structural evidence suggested that thapsigargin increases intracellular Ca\(^{2+}\) by specific and potent inhibition of the sarcoplasmic reticulum (ER) Ca\(^{2+}\)-ATPase (SERCA) (Box 2) \[51–53\]. The depletion of ER Ca\(^{2+}\) and prolonged activation of the UPR are considered to cause the massive cell death seen with thapsigargin or its analogues in various cell types \[54\]. Furthermore, a recent report suggested that overexpression of SERCA may counteract the antiviral effects of thapsigargin against two RNA viruses infecting sheep and goats (Peste des petits ruminants virus, PPRV) or birds (Newcastle disease virus, NDV) \[55\]. In *Drosophila melanogaster*, the SERCA Ca\(^{2+}\) pump is important for membrane fusion events of lysosomes \[56\], suggesting that the block of autophagy and RNA virus replication caused by thapsigargin may be related, at least in part, to changes in subcellular Ca\(^{2+}\) gradients that support vesicle fusion events. This hypothesis may be an attractive avenue for further investigations into the antiviral effects of thapsigargin.

**The pharmacology of thapsigargin: can thapsigargin be developed into a (pan-)antiviral drug?**

Taken together, the observations discussed earlier suggest that thapsigargin hits, in a unique manner, a combination of cellular processes that are essential for CoV replication (Figure 2A). It remains to be studied whether these processes can be targeted even more specifically using a combination of pathway-specific drugs, such as combinations of PERK and lysosomal inhibitors, with the aim of reducing potential side effects (Figure 2A).

The pharmacodynamics of thapsigargin in the context of depletion of Ca\(^{2+}\) from the ER and induction of cell death have been studied for four decades, primarily with the aim of using this drug in cancer therapy \[6,49\]. The synthesis and production of thapsigargin and derivatives thereof are well established, and formulations are available for application in humans \[57–59\]. A major obstacle for its potential use in antiviral therapy relates to the toxicity expected to occur in vivo. In this context, two studies have recently been performed in animal models. Oral doses of thapsigargin applied to mice 12 h before or 12 h after infection with IAV significantly improved the survival rates \[17,18\]. Starting 1 day after a lethal challenge with IAV, a daily oral application of

### Box 2. Thapsigargin and Ca\(^{2+}\)-transport

In mammalian cells, there is a >1000-fold concentration gradient of Ca\(^{2+}\) between the lumen of the ER and the cytoplasm, which is maintained by SERCA ATPase calcium pumps. These enzymes constantly transfer Ca\(^{2+}\) from the cytoplasm into the ER, where the ion supports protein folding. The lipophilic thapsigargin (Tg), within minutes, enters the cell, fully (or irreversibly) inhibits SERCA, and depletes Ca\(^{2+}\) from the ER (reviewed in \[66\]). Several studies of the atomic structures revealed that thapsigargin allosterically inhibits Ca\(^{2+}\)-ATPases as shown in Figure 1. The conserved structure of SERCA proteins consists of three cytoplasmic domains – comprising an actuator domain (A), a nucleotide-binding domain (N), and a phosphorylation (P) domain – and ten transmembrane (TM) helices. Tg binds to a groove formed by TM helices TMs, TM4, TM6, and TM7, and this interaction is stabilized by hydrophobic interactions with residues F256, L280, V283, Ile761, V769, Ile829, F834, and M839 \[77\]. An interesting question is: whether the large pattern of gene expression changes observed in Tg-treated cells \[21\] is solely due to inhibition of SERCA, or whether Tg also has additional mechanisms of actions.
Figure I. Scheme and structure models of SERCA with the Ca$^{2+}$ and thapsigargin (Tg) binding sites indicated by circles. Reproduced and adapted from [78] under a Creative Commons Attribution Non Commercial License 4.0 (CC BY-NC). Abbreviations: AMPPCP, adenylyl methylenediphosphonate; SERCA, sarco-/endoplasmic reticulum (ER) Ca$^{2+}$-ATPase.
Thapsigargin for 5 days was found to prevent infection-related death of mice infected with this virus [17]. In another study, thapsigargin was applied 15 h before a lethal dose of LPS or cecal ligation and puncture (CLP)-induced sepsis. Thapsigargin was shown to improve, in a dose-dependent manner, the survival rate of two mouse strains after 7 days [60]. Although these preclinical data on a short-term application of the drug are encouraging, more in vivo data are required to thoroughly assess the pharmacokinetics, efficacy, and toxicity of thapsigargin using animal models of infection and inflammation. This includes the application of thapsigargin in suitable SARS-CoV-2 animal models [61].

While systemic thapsigargin-mediated toxicity in humans may be appropriately addressed by using very low, single-bolus doses, or specific topical applications in the upper respiratory tract (Figure 2B), it may also be possible to design suitable prodrugs in which thapsigargin is coupled to peptides or other moieties to limit potential toxic side effects (Figure 2C,D) [62]. Thus, for
example, mipsagargin, a protease-cleavable inactive prodrug of thapsigargin, has been applied in Phase I and Phase II clinical trials for prostate or liver cancer therapy, with acceptable toxicity [63–66]. By using a similar approach, it may be feasible to develop a cell-permeable thapsigargin derivative that is specifically cleaved by viral (or specific cellular) proteases, thereby restricting the release of the active drug to virus-infected cells (Figure 2C,D).

An additional clinical benefit of thapsigargin may arise from the compound-mediated suppression of inflammatory cytokines at the post-transcriptional level by interfering with their translation or secretion [67]. These effects have been observed in CoV-infected cultured cells and in the LPS/CLP animal models [15,60]. The suppression of inflammation-mediated lung injury by the anti-inflammatory glucocorticoid dexamethasone reduces COVID-19 mortality [68]. By analogy, it will be important to find out whether low-dose thapsigargin will not only suppress CoV replication but also tissue-specific or systemic immunopathologies relevant to COVID-19 disease.

Concluding remarks and future perspective
In this opinion article we reviewed the available evidence supporting a potent antiviral effect of thapsigargin against CoVs. This antiviral effect is linked to an improved (but not complete rescue) of the cellular metabolic state and the survival of CoV-infected cells treated with this natural compound. There is also initial evidence that thapsigargin inhibits the replication of the flavivirus tick-borne encephalitis virus (TBEV), albeit by a different mechanism that involves the UPR-dependent priming of an interferon response [69]. Although many questions remain to be answered regarding virus-specific effects and the underlying antiviral actions of this compound at the molecular level (see Outstanding questions), particularly with respect to changes in intracellular membrane structures and functions in infected cells, we think it is worth pursuing further (preclinical and clinical) studies on thapsigargin and its derivatives (i) to establish topical, low-dosage, and short-term therapeutic applications, (ii) to restrict toxic effects to virus-infected cells, and (ii) to address the question of whether or not RNA viruses evolve drug-resistant variants that escape these multimodal antiviral mechanisms.

Acknowledgments
This work was supported by the following grants from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation): KR1439/3-2 and Z6188-6/2 [KFO309, P3 (to M.K. and J.Z.), project 284237345]; SFB1020/8-3 [A01 (to J.Z.), C02 (to M.K.), C03 (to M.K., U.L.), project 159775619]; and GRK 2573 [R04 (to M.L.S), R05 (to M.K.), project 416910386]. The work was also supported by the German Ministry for Education and Research (RAPID, COVINET, and DZIF TTI 01.B06, to J.Z.) and the LOEWE program of the state of Hesse (DRUID, B02 to J.Z.). Work in the laboratory of M.K. is also supported by the IMPRS program of the Max Planck Society and the Excellence Cluster CardioPulmonary Institute (EXC 2026: Cardio-Pulmonary Institute (CP), project 390649396) and the DZL/UGMLC/ILH program. The work of J.Z. and M.K. is further supported by the Von-Behring-Roentgen-Stiftung and the Pandemics Network Hesse.

Author contributions
M.K. wrote the initial draft of the article and prepared the figures. M.S.S., C.M.-B., J.M.-S., B.V.A., J.Z. and M.L.S. helped to finalize the paper. All authors approved the submitted version of the paper.

Declaration of interests
The authors declare no competing interests.

References
1. Heltz, C. et al. (2020) Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 21, 421–438
2. Marciniec, S.J. et al. (2022) Pharmacological targeting of endoplasmic reticulum stress in disease. Nat. Rev. Drug Discov. 21, 115–140
3. Karagoz, G.E. et al. (2019) The unfolded protein response: detecting and responding to fluctuations in the protein-folding capacity of the endoplasmic reticulum. Cold Spring Harb. Perspect. Biol. 11, a032886
4. Grootjans, J. et al. (2016) The unfolded protein response in immunity and inflammation. Nat. Rev. Immunol. 16, 469–484

Outstanding questions
Are SERCA and SERCA-dependent processes such as Ca2+-signaling, Ca2+-dependent regulation of cellular factors or enzymes, and subcellular changes in Ca2+ concentrations relevant for thapsigargin-mediated antiviral activities? What are the roles of local Ca2+-sensing or effector mechanisms inside organelles and at their interfaces?

How is cell morphology affected by thapsigargin early upon viral replication, and, related to this, can thapsigargin lead to the resolution of already established ROs? Can these questions be solved by 3D high-resolution imaging, including advanced electron microscopy?

Present evidence suggests that thapsigargin antiviral activity crucially relies on the inhibition/activation of several cellular processes, but it is unclear whether some of these are more important than others. Does thapsigargin hit a process or a specific molecular event that is common to all enveloped viruses, even though they have highly divergent life cycles (e.g., CoV or IAV)? Can these issues be addressed by meta-analyses of functional genome-wide genetic screens performed in various infection models?

Several hACE2-transgenic mice and also mouse-adapted SARS-CoV-strains are now available. Will thapsigargin suppress the replication of SARS-CoV-2 in animal models of COVID-19 disease? What are the long-term consequences?

Multiple chemical analogues of thapsigargin have been synthesized recently and can be studied in RNA virus infection models with respect to replication versus cell survival. Can they be used to separate thapsigargin-mediated cytotoxicity from its antiviral effects?

Can thapsigargin analogues be designed in a way that they are cleaved, after internalization, by cell-specific or CoV main proteases?

Can thapsigargin be specifically targeted to sites of infection in vivo? For example, can (inactive) peptide–thapsigargin conjugates be targeted to cell-surface molecules only expressed on CoV-infected cells?
58. Chu, H. et al. (2017) Scalable synthesis of (-)-thapsigargin. ACS Cent. Sci. 3, 47–51
59. Lopez, C.G. et al. (2018) Use of a temporary immersion bioreactor system for the sustainable production of thapsigargin in shoot cultures of Thapsia garganica. Plant Methods 14, 79
60. Wei, Y. et al. (2019) Pharmacological preconditioning with the cellular stress inducer thapsigargin protects against experimental sepsis. Pharmacol. Res. 141, 114–122
61. Lee, C.Y. and Lowen, A.C. (2021) Animal models for SARS-CoV-2. Curr. Opin. Virol. 48, 73–81
62. Zhao, Z. et al. (2020) Targeting strategies for tissue-specific drug delivery. Cell 181, 151–167
63. Doan, N.T. et al. (2015) Targeting thapsigargin towards tumors. Steroids 97, 2–7
64. Mahalingam, D. et al. (2019) A phase II, multicenter, single-arm study of mipsagargin (G-202) as a second-line therapy following sorafenib for adult patients with progressive advanced hepatocellular carcinoma. Cancers (Basel) 11, 833
65. Mahalingam, D. et al. (2016) Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. Br. J. Cancer 114, 886–894
66. Isaacs, J.T. et al. (2021) Mipsagargin: The beginning not the end of thapsigargin prodrug-based cancer therapeutics. Molecules 26, 7469
67. Schmitz, M.L. et al. (2019) The crosstalk of endoplasmic reticulum (ER) stress pathways with NF-kappaB: complex mechanisms relevant for cancer, inflammation and infection. Biomedicines 6, 58
68. Cain, D.W. and Oldfield, J.A. (2020) After 62 years of regulating immunity, dexamethasone meets COVID-19. Nat. Rev. Immunol. 20, 587–588
69. Caretti, T. et al. (2019) Viral priming of cell intrinsic innate antiviral signaling by the unfolded protein response. Nat. Commun. 10, 3899
70. Quinca, G. et al. (2013) Hepr depletion protects from protein aggregation by up-regulating autophagy. Biochem. Biophys. Acta 1833, 3295–3305
71. Wilkinson, S. (2003) Emerging principles of selective ER autophagy. J. Mol. Biol. 332, 185–205
72. Bhattacharya, A. and Qi, L. (2019) ER-associated degradation in health and disease – from substrate to organism. J. Cell Sci. 132, jcs22860
73. Christianson, J.C. et al. (2012) Defining human ERAD networks through an integrative mapping strategy. Nat. Cell Biol. 14, 93–105
74. Chino, H. and Mizushima, N. (2020) ER-phagy: quality control and turnover of endoplasmic reticulum. Trends Cell Biol. 30, 284–296
75. Ferro-Novick, S. et al. (2021) ER-phagy, ER homeostasis, and ER quality control: implications for disease. Trends Biochem. Sci. 46, 630–639
76. Nakatogawa, H. (2020) Mechanisms governing autophagosome biogenesis. Nat. Rev. Mol. Cell Biol. 21, 439–456
77. Aguayo-Ortiz, R. and Espinoza-Fonseca, L.M. (2020) Linking biochemical and structural states of SERCA: achievements, challenges, and new opportunities. Int. J. Mol. Sci. 21, 4146
78. Zhang, Y. et al. (2020) Cryo-EM structures of SERCA2b reveal the mechanism of regulation by the luminal extension tail. Sci. Adv. 6, eabb0147